A hallmark of many chronic inflammatory and autoimmune diseases is that there is an impaired resolution of inflammation and return to the steady state. The infusion of high doses of pooled serum IgG preparations from thousands of donors [intravenous immunoglobulin (IVIG) therapy] has been shown to induce resolution of inflammation in a variety of chronic inflammatory and autoimmune diseases, suggesting that IgG molecules can instruct the immune system to stop inflammatory processes and initiate the return to the steady state. The aim of this review is to discuss how insights into the mechanism of IVIG activity may help to understand the molecular and cellular pathways underlying resolution of inflammation. We will put a special emphasis on pathways dependent on the IgG F C domain and IgG sialylation, as several recent studies have provided new insights into how this glycosylation-dependent pathway modulates innate and adaptive immune responses through different sets of C-type or I-type lectins.
Introduction
A critical feature of a balanced immune response is that a phase of inflammation, triggered for example through microbial infection, will be self-limiting and followed by a phase of resolution of inflammation once the pathogen is cleared. Whereas the initial inflammatory response is essential to limit pathogen spread and instruct the adaptive immune system to generate an appropriate effector and memory response, the following phase of resolution of inflammation is essential to regain tissue and immune system homeostasis and induce wound healing.
Although the triggers and checkpoints controlling the initiation of an inflammatory response have been well studied, the critical molecular and cellular players necessary for initiating resolution of inflammation are much less understood. Knowing the details of the pathways responsible for returning to the steady state is critical for interfering with excessive and self-destructive inflammatory responses. Prime examples for such deregulated immune responses are autoimmune responses, in which the immune system reacts against healthy tissues of the host. Once tolerance towards self is lost, the continuous presence of auto-antigens drives a positive feedback loop, further enhancing inflammation.
Knowing the key signals that switch the immune system to a state of resolution of inflammation may open new therapeutic avenues to treat unwanted inflammatory responses. One possible route of identifying the pathways involved in resolution of inflammation is through studying long-known and effective therapeutic interventions effective in a wide variety of chronic inflammatory and autoimmune diseases.
A prime example for such a therapeutic intervention, which has been used for decades as an anti-inflammatory and immunomodulatory drug, is the infusion of high doses of pooled IgG preparations from the serum of thousands of healthy donors [intravenous immunoglobulin (IVIG) therapy] (1) (2) (3) (4) . This therapy is a licensed treatment for a variety of autoimmune diseases including immunothrombocytopenia (ITP), Guillain-Barré syndrome, Kawasaki disease and chronic inflammatory demyelinating polyneuropathy (CIDP) (5-7). Offlabel uses include a wide spectrum of chronic inflammatory and autoimmune diseases, although many of the studies describing the successful use of IVIG under these conditions contain small patient cohorts or represent case studies. Of note, in some of the diseases where IVIG has been shown to be effective, such as ITP and epidermolysis bullosa acquisita (EBA), IgG auto-antibodies play a crucial role in the disease process as well (8, 9) . This suggests that under certain conditions, IgG antibodies can trigger both initiation as well as resolution of inflammation.
With respect to IgG-dependent initiation of inflammation it has become clear that several factors influence the ability of IgG auto-antibodies to induce inflammation and tissue pathology (10) (11) (12) . One such factor is the IgG subclass of the auto-antibody as different IgG subclasses interact differentially with individual F C γ receptors (F C γRs) expressed on innate immune effector cells. The family of F C γRs comprises several activating (F C γRI, III, IV in mice; F C γRIa, IIa, IIc, IIIa in humans) and one inhibitory receptor (F C γRIIb in mice and humans) (Fig. 1A) . In addition, human neutrophils express F C γRIIIb, which is a glucose 6-phosphate isomerase-linked receptor with no autonomous signaling activity. In humans, allelic variants of F C γRIIa (with a histidine or arginine at position 131) and F C γRIIIa (with a valine or phenylalanine at position 158) have an altered affinity for select human IgG subclasses. For example, the F C γRIIa-131H allele binds human IgG2 much better than F C γRIIa with an arginine residue at this position and the F C γRIIIa-158V allele binds human IgG3 and IgG1 with much higher affinity than the F C γRIIIa-158F variant (13, 14) . With the notable exception of NK cells, the inhibitory F C γRIIb is usually co-expressed with different combinations of activating F C γRs and counterbalances cell activation. As mouse IgG1 antibodies bind with a higher affinity to the inhibitory F C γRIIb than to the activating F C γRIII, they have a lower capacity to trigger innate immune effector cell activation (15) . In contrast, mouse IgG2a antibodies have a lower affinity for F C γRIIb and can bind to several activating F C γRs (F C γRI, III, IV) with a much higher affinity, resulting in an increased activity. This affinity-based model of predicting IgG subclass activity has been referred to as the A/I ratio model (16) . In this model, a relative activity score is calculated by dividing the affinity of an IgG subclass for an activating F C γR Fig. 1 . Mouse and human type I and type II F C Rs. (A) Type I F C Rs bind IgG, belong to the immunoglobulin superfamily and can be separated into activating and inhibitory receptors. Whereas all mouse and the majority of human activating F C γRs have to associate with the common F C Rγ chain (γ 2 ) to trigger activating signaling pathways via an ITAM, human F C γRIIa and IIc can signal autonomously via an ITAM motif in the receptor α-chain (α). The inhibitory F C γRIIb transmits inhibitory signaling pathways via an intracellular ITIM. Mouse F C γRIV and human F C γRIIIa have the capacity to recognize IgG glycosylation variants without fucose with higher affinity. F C γRIIa (131R/H) and IIIa (158F/V) exist in different allotypic forms, which impact IgG subclass binding. (B) Type II F C Rs belong to the C-type (SIGN-R1, DC-SIGN, DCIR, CD23) and I-type lectin (CD22) family and play an important role in the immunomodulatory and anti-inflammatory pathway triggered through sialic acid-rich IgG glycovariants. See text for further details.
by the affinity of this subclass for the inhibitory F C γRIIb; the higher the value of the resulting ratio, the higher the predicted activity of the IgG subclass. Consistent with such a model, IgG1 activity is enhanced most dramatically in mice deficient in F C γRIIb, whereas IgG2a activity is only mildly affected (15) . An important difference between mice and humans is that human innate immune effector cells express lower levels of F C γRIIb, which would suggest a lower level of negative regulation through this receptor. However, human IgG subclasses also have a lower overall affinity for activating F C γRs (with the exception of certain allelic variants) which may counterbalance an unwanted activation of immune cells (17) .
Apart from the difference of IgG subclasses in binding to individual F C γRs, it has become clear that also within one IgG subclass dramatic differences with respect to F C γR binding and triggering of pro-inflammatory responses can be observed if antibodies are differentially glycosylated (18) . All IgG molecules have a single sugar domain attached to each of the two IgG heavy chains in the CH2 domain (linked to the asparagine 297 residue) of the IgG molecule. This sugar domain has a constant core structure consisting of N-acetylglucosamine and mannose residues and is essential for maintaining the IgG F C domain in a functional conformation (19) . In addition, varying levels of terminal galactose and sialic acid residues and branching fucose and GlcNac residues may be present in select IgG glycovariants. IgG antibodies with a high level of terminal sialic acid residues were shown to lose affinity for certain activating F C γRs, while IgG glycovariants without fucose have a dramatically increased binding for the activating F C γRIIIa in humans and F C γRIV in mice (Fig. 1A) (3, 4, 19) . Finally, the pro-inflammatory activity of select IgG subclasses may be influenced by their ability to activate the complement pathway. Thus, mouse IgG1 antibodies cannot activate the complement system via C1q binding, whereas IgG2a and IgG2b antibodies efficiently trigger complement activation via the classical pathway. Although it is hard to compare the four different IgG subclasses in mice and humans, similar general rules apply. Human IgG1 and IgG3, for example, bind well to activating F C γRs and can activate the complement pathway, whereas IgG2 and IgG4 molecules bind less well to activating F C γRs and are not able to activate the complement system efficiently.
In contrast to the in-depth knowledge about the mechanisms underlying the pro-inflammatory activity of IgG, we are only beginning to understand which pathways may be responsible for triggering the resolution of inflammation. As IVIG is effective in a wide variety of chronic inflammatory and autoimmune diseases, in many of which the underlying mechanisms of disease pathology are not known in detail, we will focus on select autoimmune diseases for which in-depth insights into the underlying disease processes are known, allowing us to identify IVIG-dependent alterations of relevant immune responses. Given the complexity of the different types of diseases, it is not surprising that disease-specific pathways and receptors have been identified through which IVIG may mediate its immunomodulatory activity and there are excellent reviews covering this complexity of mechanisms (1, (20) (21) (22) .
In this review, we will focus on mechanisms dependent on the IgG F C (F C γ) domain, which have been shown to be critical for the therapeutic effect of IVIG in modulating human B-cell survival (23) , ameliorating ITP and Kawasaki disease, and preventing inflammation in mouse models such as inflammatory arthritis (24) (25) (26) (27) (28) (29) , nephrotoxic nephritis (30) , ITP (31, 32) , antibody-dependent acute lung injury (33) and experimental autoimmune encephalomyelitis (EAE) (34) . Furthermore, we will put an emphasis on how sialylated IgG glycoforms within IVIG preparations contribute to this immunomodulatory activity impacting both the innate and the adaptive arms of the immune system and how a variety of novel receptors, also called type II F C receptors (F C Rs), contribute to this activity. In contrast to the classical type I F C Rs, type II F C Rs belong to the C-type (calcium-dependent ligand binding) and I-type [immunoglobulin superfamily lectins such as sialic acid-binding immunoglobulin-like lectins (SIGLEC)] lectin family and have been identified originally by their ability to bind certain sugar structures (Fig. 1B) (3, 35) .
Models of IVIG-dependent modulation of the IgG-F C γR axis
Different types of autoimmune diseases, such as rheumatoid arthritis, multiple sclerosis and skin-blistering diseases, are characterized by organ-specific autoimmune pathologies (11) . Thus, in vivo studies are critical to allow insights into how IVIG impacts tissue-specific autoimmune responses as in vitro studies may only partially mimic the inflammatory milieu and the complex interactions of immune cells with nonhematopoietic organ-specific cell types.
One caveat of using human IVIG preparations in animal models in vivo is that the infusion of human IgG will trigger a mouse anti-human antibody response that may make it difficult to interpret the results if IVIG is used repetitively over a prolonged period of time. Thus, most of the studies investigating F C -dependent effects of IVIG activity in vivo have used passive models (in which auto-antibodies are injected) of auto-antibody-induced tissue inflammation, such as inflammatory arthritis, EBA and ITP (Fig. 1 ). Although these studies are limited to identifying IVIG-dependent pathways of modulating innate immune effector cells, they have provided important insights into the complex mechanisms of IVIG activity in vivo.
Mechanisms of IVIG-mediated modulation of inflammatory arthritis
In mice, inflammatory arthritis is a disease in which auto-antibodies specific for self-antigens, such as collagen or glucose 6-phosphate isomerase (G6PI), trigger joint inflammation and bone destruction (36) . One of the most common models is the so-called KBxN serum transfer arthritis model, in which G6PI-specific IgG1 and IgG2b auto-antibodies in the serum from mice with arthritis are transferred to healthy mice, which develop a transient form of the disease (37, 38) .
In this model, activating F C γRs and complement components C3a and C5a are critical for joint inflammation and bone destruction via the recruitment of neutrophils and myeloid cells (37, 39, 40) . The inhibitory F C γRIIb restricts excessive inflammation by limiting the innate immune effector cell activation that is triggered by immune complexes binding to activating F C γRs (41) . IVIG has been demonstrated to be very efficient in suppressing joint inflammation under preventive
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and therapeutic treatment schemes and the IgG F C domain was shown to be key for this anti-inflammatory activity (27) (28) (29) 41) . In 2006, Kaneko et al. demonstrated that removing the sugar moiety that is associated with the IgG F C domain impairs the anti-inflammatory activity of IVIG and that terminal sialic acid residues are responsible for this effect (28) . Of note, IVIG could not be replaced by other serum proteins, containing a similar highly sialylated sugar structure, suggesting that both the sugar moiety and the IgG molecule itself were critical for the immunomodulatory activity.
Further studies by Anthony et al. demonstrated that a monoclonal IgG F C domain enriched for sialic acid achieved the same therapeutic activity and that the C-type lectin SIGN-R1 [specific intracellular adhesion molecule 3-grabbing nonintegrin (SIGN)-related 1] may serve as a receptor for IgG glycoforms that are rich in sialic acid (25, 26) . As lectins are defined by their capacity to bind sugar structures, this seemed like a plausible candidate although not the interaction with the sugar moiety alone but rather with the whole IgG molecule was essential, arguing for a novel mode of binding, which will be discussed later. SIGN-R1-deficient mice were no longer protected by IVIG therapy from auto-antibody-dependent joint inflammation; however, the reconstitution of SIGN-R1-deficient mice with the human orthologue to SIGN-R1, DC-SIGN (dendritic cell SIGN), reconstituted IVIG activity, suggesting that the findings obtained in this mouse model may also be of relevance for humans (26) . As colonystimulating factor 1 (CSF-1)-deficient and splenectomized mice were no longer protected by IVIG, this suggested that a spleen-resident CSF-1-dependent and SIGN-R1-positive cell population acted as a sensor for highly sialylated IgG glycovariants ( Fig. 2A) (26, 41) . Moreover, it was demonstrated that this sialic acid specific pathway was dependent on IL-33 (24) . Although IL-33 was initially described as an alarmin, which is released from damaged tissues and potentiates inflammation, more recent studies have shown that IL-33 also plays an important role for tissue homeostasis and repair during the steady state and potentiates T h 2 responses (42). Furthermore, the receptor for IL-33, ST2, is constitutively expressed on some T reg cells, eosinophils, basophils, mast cells and innate lymphoid cells (ILCs), which respond to IL-33 by secreting T h 2 cell cytokines including IL-4 and IL-10, for example (42, 43) . Consistent with this latter scenario, sialylated IVIG-dependent IL-33 release was shown to induce basophil expansion and require IL-4 and the IL-4 receptor (24) . As IL-4 is known to up-regulate the inhibitory F C γRIIb on myeloid cells (44) , which express the IL-4R especially at sites of inflammation (45) , these studies provided a comprehensive picture of how a preventive IVIG infusion may inhibit an auto-antibody-dependent inflammatory response ( Fig. 2A) .
Whereas the requirement of SIGN-R1 for IVIG activity was almost absolute under preventive treatment conditions, instead SIGN-R1 deficiency rather delayed IVIG activity if mice with established joint inflammation were treated (26, 29) . Thus, additional cell surface receptors may be involved for IVIGdependent resolution of inflammation. In line with this model, different cell surface receptors belonging to the C-or I-type lectin family were shown to be responsible for IVIG activity in other model systems (see later paragraphs). Moreover, Campbell et al. have identified an F C domain-dependent but IgG glycosylation-independent mechanism of IVIG activity in inflammatory arthritis (27) . Further studies will be necessary to fully elucidate the IVIG-dependent activities in this model system also with respect to the protection from bone destruction, which operates through different innate immune effector cells and activating F C γRs (40) .
Of interest for efforts to improve IVIG activity, two independent studies demonstrated that increasing the sialic acid content of IgG glycoforms in commercial IVIG preparations or on recombinant monoclonal IgG1 F C domains resulted in an enhanced anti-inflammatory activity (25, 46) . Further in line with these results, an IgG F C domain mutant in which the phenylalanine residue at position 241 is exchanged for an alanine (F241A) has been shown to mimic the effect of a high level of IgG sialylation and to reduce inflammation via SIGN-R1 or DC-SIGN (34) .
Apart from inflammatory arthritis, a recent study demonstrated that IgG sialylation and IL-33 are also involved in IVIG-mediated protection from auto-antibody-triggered nerve injury (47) . Supporting the relevance of these observations for human patients, IVIG therapy triggered IL-33 release in rheumatoid patients. Furthermore, an expansion of basophils was noted in some but not all patients, suggesting that similar, but not identical immunomodulatory pathways are operative in humans (48) . More work in well-defined human patient cohorts may help to investigate this in greater detail in the future.
Therapeutic activity of IVIG in EBA
EBA is a rare chronic autoimmune disease affecting the skin and mucosa (49, 50) . It is characterized by widespread blister formation and a neutrophil infiltrate due to the presence of auto-antibodies specific for collagen type VII, which ultimately results in a separation of the dermis from the epidermis (11, 50) . Of note, IgG1 and IgG4 subclasses were shown to dominate the collagen type VII specific antibody response (51) (52) (53) . Despite the fact that IgG4 antibodies interact only weakly with F C γRs and the complement system there is convincing evidence that they contribute to tissue pathology (54) . Although results from large human clinical trials are not available, several studies have demonstrated that IVIG is a highly efficient treatment for several skin-blistering diseases, including EBA (9, 55) . Similar to inflammatory arthritis, F C γRs and activated complement components are critical for auto-antibody-dependent inflammation and IVIG has been shown to suppress inflammation under preventive treatment conditions and to enhance resolution of inflammation under therapeutic treatment conditions in mouse model systems (29, (56) (57) (58) .
Further in line with results from the inflammatory arthritis model, IVIG activity was impaired if sialylated IgG glycoforms were depleted from IVIG preparations but activity was enhanced if hypersialylated IVIG was used as a therapeutic agent (29, 46) . Moreover, IVIG activity was delayed but not impaired if SIGN-R1-deficient mice were treated after the onset of disease, again arguing for the involvement of additional receptors specific for sialic acid-rich IgG glycovariants. Consistent with the inflammatory arthritis model, F C γRIIb-deficient mice showed enhanced inflammation and were no longer protected by IVIG infusion (29) . Thus, it seems that similar pathways, with respect to limiting auto-antibody-mediated activation of innate immune effector cells are involved in IVIG-dependent amelioration of inflammatory arthritis and EBA.
Apart from the passive transfer of antibodies specific for collagen type VII, Hirose et al. have studied IVIG activity in an active (immunization-induced) model of EBA allowing them to determine how IVIG therapy affects auto-antibody responses in vivo (56) . They could demonstrate that IVIG therapy reduced both the quantity and quality of the auto-antibody response. Thus, under IVIG therapy, collagen specific IgG subclasses with a high complement-fixing ability (IgG2a and IgG2b) were reduced while levels of IgG1 antibody specific for collagen were maintained. Consistent with this change in IgG subclass composition, a lower level of complement deposition was observed in the skin.
Moreover, mouse IgG1-dependent effector responses are strongly inhibited by F C γRIIb, resulting in a lower level of innate immune effector cell activation (15) . Finally a 
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down-modulation of activating F C γRIV was observed, further reducing the capacity of IgG2a and IgG2b auto-antibodies to induce monocyte, macrophage and neutrophil activation (16, 38, 59) . Although the authors did not study if IgG glycoforms containing sialic acid are responsible for this modulation of auto-antibody production by B cells, a recent study demonstrated that CD23 [a member of the member of the C-type lectin-like domain (CTLD) superfamily; also known as the low-affinity IgE receptor] on B cells has the capacity to bind sialylated IgG glycoforms and alters B-cell responses through up-regulation of the inhibitory F C γRIIb on B cells (60) . Furthermore, Seite et al. noted that sialylated IVIG glycovariants modulated B-cell signaling and survival via CD22 (SIGLEC-2) (23).
Thus, the active EBA model system may allow us to obtain new insights into IVIG-dependent immunomodulatory pathways and, given the similarity of the disease processes and therapeutic activity of IVIG in humans and mice and the clinical efficacy of IVIG, this may lead to new insights with a high relevance for the human clinical situation.
Mechanisms of IVIG-mediated modulation of ITP
ITP is an autoimmune disease in which antibodies specific for platelet surface antigens result in a rapid clearance of platelets through the mononuclear phagocytic system without major systemic inflammation (2, 11, 61, 62) . ITP was the disease in which it was noted for the first time that a high-dose infusion of IVIG can inhibit auto-antibody-dependent immune pathology (4, 8, 63, 64) . These results were confirmed by later studies in adult ITP patients, which resulted in the use of IVIG as a standard treatment for ITP and several other autoimmune and chronic inflammatory diseases (6) . Later clinical trials in ITP and Kawasaki disease demonstrated that the IVIG F C -fragment is sufficient for this immunomodulatory activity in vivo, providing strong evidence that mechanisms dependent on the IgG F C domain are critical for IVIG activity in humans in vivo (65) (66) (67) .
The most common research models used to study ITP in vivo use the passive transfer of a rat IgG1 antibody specific for mouse CD41 (antibody clone MWreg30) or a mouse monoclonal antibody called 6A6, which was derived from a mouse strain spontaneously developing ITP and is directed against a platelet-associated integrin (68) . The 6A6 antibody is originally of a mouse IgG2c subclass, but was also switched to mouse IgG1, IgG2b and IgG3 subclasses (15, 59) . In humans, the platelet-specific immune response is heterogeneous but in the majority of patients, IgG1 auto-antibodies directed against the platelet glycoproteins GPIIb/IIIa can be detected. In small subgroups of patients, IgG2, IgG3 and IgG4 platelet-specific immune responses may dominate, suggesting that during the initiation of autoimmunity different T h cell responses may have been operative (69) .
In the mouse model systems, activating F C γRs were demonstrated to be responsible for auto-antibody-mediated platelet depletion, which is in line with clinical data in humans (15, 31, 38, 59, 70, 71) . Further, consistent with the data from human ITP patients, IVIG treatment of mice with ITP was sufficient to restore platelet counts under preventive and therapeutic treatment conditions (28, 29, 31, 72) . Moreover, several studies demonstrated that the IVIG F C -fragment was sufficient for this effect, demonstrating that similar pathways are underlying IVIG activity in mice and humans (31, 32) .
More in-depth mouse studies revealed that the inhibitory F C γRIIb is essential for IVIG activity in some but not all ITP model systems, suggesting that the threshold set through coexpression of F C γRIIb together with activating F C γRs can be an essential component of IVIG-dependent immune modulation (31, 73, 74) . In a human clinical trial, IVIG infusion rather down-regulated the activating F C γRIIIa but did not change F C γRIIb expression, suggesting that species-specific and/ or disease-specific differences need to be considered (75) . Arguing for the latter scenario, IVIG up-regulated F C γRIIb expression on B cells in patients with CIDP but down-regulated several activating F C γRs in Kawasaki disease patients and in a mouse model of EBA (56, 76, 77) . In a mouse model of nephrotoxic nephritis, both an up-regulation of F C γRIIb and a down-modulation of F C γRIV were noted (30) . Regardless, the effect of changed F C γR expression is a lower capacity of immune complexes to activate innate immune effector cells by changing the ratio of activating F C γRs to the inhibitory F C γRIIb (the so-called A/I ratio) (15) .
Apart from F C γRIIb, IVIG glycosylation and, most importantly, the terminal sialic acid residues were demonstrated to be essential for IVIG-mediated inhibition of ITP under preventive and therapeutic treatment conditions, although sialic acid-independent activities of IVIG were noted in the MWreg ITP model system by some but not all groups (29, (78) (79) (80) . Enriching IVIG for glycoforms rich in sialic acid resulted in a 10-fold enhanced ability to suppress auto-antibodydependent platelet depletion (46) . Similar to the results for IVIG-mediated resolution of inflammation in inflammatory arthritis, a differential requirement for SIGN-R1 was observed if preventive or therapeutic treatment schemes were investigated. Whereas under preventive treatment conditions, SIGN-R1 was essential for IVIG activity, this was not the case under therapeutic treatment conditions. Furthermore, neither spleen-resident macrophages, IL-4, IL-33 nor basophils were required for IVIG activity, suggesting that, in models without major inflammation, other immunomodulatory pathways are responsible for IVIG activity (Fig. 2B) (78, (81) (82) (83) . As liverresident monocytes or macrophages may be responsible for auto-antibody-dependent platelet depletion (84), one possible but at present speculative model would be that IVIG directly acts on these effector cells under therapeutic conditions without an intermediate sensing cell population (Fig. 2B) .
More recently, a fully humanized mouse model of ITP was developed, allowing assessment of how IVIG modulates the human immune system in vivo (32) . In this model system, immunodeficient NOD/SCID/γc/F C Rγ-knockout mice are reconstituted with a human immune system through transplantation with human hematopoietic stem cells at the day of birth. As these animals lack functional mouse-derived activating F C γRs, they allow specific study of the interaction of auto-antibodies with human innate effector cells. By using human IgG1, 2, 3, and 4 subclass-switch variants of the same platelet-specific antibody, it was demonstrated that especially IgG1 and IgG3 antibodies were pathogenic and caused a severe thrombocytopenia, suggesting that activating F C γRs played a critical role in this process (32) . Indeed, auto-antibody-dependent platelet depletion could be inhibited with antibodies blocking IgG binding to human activating F C γRs or by IVIG therapy, consistent with the data obtained in human ITP patients and classical mouse model systems. More interestingly, IVIG activity was dependent on the F C domain and sialylation, suggesting that the sialic aciddependent pathway of IgG-dependent immunomodulation is of high relevance for the human immune system. Whether the human orthologue to SIGN-R1 (DC-SIGN) or other cell surface receptors are critical for IVIG activity in this humanized mouse model will need to be studied in the future. Of further interest, it was demonstrated recently that in patients with fetal or neonatal alloimmune thrombocytopenia (FNAIT), where antibodies specific for platelet alloantigens of the fetus are generated by the mother, especially afucosylated platelet-specific IgG glycovariants were associated with overt autoimmune disease (85, 86) . As these IgG glycoforms show a specific enhancement for binding to human F C γRIIIa and F C γRIIIb, humanized mouse models may be an excellent tool for studying if these antibodies indeed work selectively via these two human F C γRs.
IVIG-mediated modulation of T-cell responses
Apart from the appearance of auto-antibodies, a paucity of T reg cells is another hallmark of many autoimmune diseases (87, 88) . A loss of T reg cells results in a chronic inflammatory disease called IPEX (immunodysregulation polyendocrinopathy X-linked syndrome), which can be fatal in its most severe form because of uncontrolled and self-reactive T-and B-cell responses (88) (89) (90) (91) . Thus, one aim of restoring immune tolerance and resolution of inflammation is through induction or restoration of T reg cell responses. Of interest for the topic of this review, IVIG therapy has been shown to increase T reg populations in patients with rheumatic disorders (92) and the Guillain-Barré syndrome (93) and in various mouse model systems of T-cell-dependent autoimmunity (34, (94) (95) (96) .
More recently, pathways dependent on the IgG F C domain and glycosylation have been suggested to be involved in T reg cell expansion (34, 96) . Apart from pathways specific for IgG glycosylation, it has been shown by the work of De Groot et al. that certain amino acid motifs (Tregitopes) in the IgG F C domain can induce the expansion of T reg cells if they are presented in the context of MHC molecules on DCs (97) . This interesting pathway of IgG-dependent T reg cell expansion has been summarized elsewhere and the interested reader is directed to these review articles (98, 99) . Instead we will focus on two in vivo model systems where the IVIG-dependent pathway of T reg cell expansion was studied in greater detail (Fig. 2) .
In the first system, Massoud et al. used a model of acute airway hyper-responsiveness (AHR), in which mice are presensitized with a model antigen followed by intra-tracheal challenge with the antigen (96) . IVIG is able to suppress these responses and it was demonstrated that T reg cells played a crucial role in this process. Interestingly, this effect was dependent on IVIG sialylation, because neuraminidase-treated IVIG was not able to induce T reg cells and because IVIG enriched in sialic acid displayed an enhanced anti-inflammatory activity. Furthermore, lung DCs up-regulated the DC immunoreceptor (DCIR; another member of the C-type lectin superfamily), but not SIGN-R1, during IVIG therapy of AHR in a sialic aciddependent manner. Proving the critical role of DCIR for IVIG activity (100), DCIR-deficient mice were no longer protected by IVIG from AHR development (96) . Of note, DCIR was shown to directly bind to sialylated IVIG glycoforms, establishing that DCIR may be a bona fide receptor for sialylated IgG glycoforms (Fig. 3A) . Establishing a direct role of DCs, an intra-tracheal injection of IVIG enriched in sialic acid also protected mice from lung inflammation via the induction of T reg cells.
In the second study, Fiebiger et al. investigated the effect of IVIG on the induction of T reg cell responses in a model of EAE (34) . EAE is induced by immunization of mice with proteins or peptides derived from nerve cells and is characterized by a largely T-cell-dependent inflammatory process leading to progressive paralysis. IVIG treatment can ameliorate or block EAE development, which is paralleled by an expansion of T reg cells (34, 94, 101) . Consistent with the AHR model, treating EAE with IVIG resulted in T reg cell expansion, which was dependent on sialylated IgG glycovariants. Arguing for a role of SIGN-R1 in this process, no T reg cell expansion was observed in SIGN-R1-deficient mice. Similar to the inflammatory arthritis model, IL-33 played a critical role in this process (Fig. 3B ). These findings are in line with a study demonstrating that IL-33 can support the generation of T reg cells via stimulating IL-2 secretion by conventional DCs, although this was not investigated in the study (102) .
Demonstrating the therapeutic potential of this finding, the injection of IL-33 was shown to ameliorate experimental colitis in mouse model systems (103, 104) . Consistent with this model, IVIG therapy of experimental colitis was able to suppress intestinal inflammation through induction of IL-33 (34) . More recently, IVIG was demonstrated to induce IL-33 expression in rheumatic patients, suggesting that this IVIGdependent pathway may also be operative in humans, although the exact downstream molecular and cellular players need to be established in future studies (48) .
Conclusions and open questions
In summary, the data provided by the work of many groups in human patients and a wide variety of in vivo mouse model systems have firmly established the potent immunomodulatory function of the IgG F C domain on innate immune responses. With respect to IVIG-dependent modulation of adaptive immune responses, there is evidence that similar rules may apply. For example, studies demonstrating an IgG sialylationdependent modulation of B-cell function (23, 60, (105) (106) (107) (108) and T reg cell expansion (34, 96) argue for a broad effect of sialylated IgG glycovariants on both arms of the immune system. In addition, the role of sialylated IgG glycovariants for IVIG activity has been established in many classical and humanized mouse model systems, although F C -dependent but sialylation-independent pathways have been shown to operate under certain conditions. Naturally, studies in inbred mouse model systems need to be interpreted with caution as both mouse and human IgG subclasses and type I and type II F C γRs cannot be compared directly. Nonetheless, data in human autoimmune patient cohorts, demonstrating that a reduced level of auto-antibody sialylation correlates
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with increased disease activity and may even be a biomarker with predictive value, provide first clues that sialylated IgG glycoforms may have a similar function in humans (109) (110) (111) (112) .
When it comes to the underlying pathways of how sialylated IgG species may function the situation seems very complex, as disease-specific pathways were suggested to operate. Thus, different cell surface receptors, including SIGN-R1 (and its human orthologue DC-SIGN) and DCIR, have been shown to be critical for the sialylation-dependent anti-inflammatory activities of IVIG in a disease-specific manner (Fig. 3 ). Both receptors have been shown to bind sialylated IgG, which may indicate that, depending on the disease, different types of receptors specific for sialylated IgG are up-regulated at the site of inflammation or that different cell subsets are critical for IVIG activity in different autoimmune diseases.
Cell populations that have been repeatedly shown to be involved in IVIG activity are DCs and/or macrophages, which can express DC-SIGN and DCIR. Indeed, transfer of DCs (or macrophages) primed with IVIG or sialylated IgG F C -fragments was able to suppress autoimmune pathology in models such as inflammatory arthritis, AHR, ITP and EAE (24, 34, 96, 113, 114) . As DCs are essential for the induction of T reg cell responses, this would also be consistent with the expansion of T reg cells upon IVIG infusion in mice and humans (88, 115) .
As we have pointed out, there are several areas in which conflicting data have been reported, and need to be studied in the future. Apart from understanding under which conditions sialic acid-dependent and sialic acid-independent pathways underlie IVIG activity, this also includes the impact of IgG sialylation on IgG structure and the mechanism of binding of sialylated IgG to type II F C Rs (116, 117) . Ultimately, clinical trials with hypersialylated IVIG, monoclonal IgG molecules or isolated F C domains in human autoimmune patients will be necessary to demonstrate that this IgG glycoform has an anti-inflammatory activity in humans. In the meantime, well-designed immunomonitoring of human autoimmune patients undergoing IVIG therapy may help to provide useful hints with respect to which parameters differentiate responders from non-responders as has been done before (109) .
Regardless of these open questions, studying the function of sialylated IgG species has uncovered a variety of new immunoregulatory pathways, which may help to understand and modulate resolution of inflammation in the future.
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